Fig. 1Bland-Altman plot for the training dataset (A) and the jackknife-based validation dataset (B) in a population of subjects with different clinical characteristics (nondiabetic [ND] and type 2 diabetes mellitus [T2DM] groups). The continuous line represents the mean of the difference between minimal model glucose effectiveness (SG) and calculated SG (CSG); the dash-dotted lines represent the limits of agreement (mean±1.96×standard deviation).
Fig. 2Bland-Altman plot for the previous gestational diabetes mellitus group (women) at baseline (A) and follow-up (B). The continuous line represents the mean of the difference between minimal model glucose effectiveness (SG) and calculated SG (CSG); the dash-dotted lines represent the limits of agreement (mean±1.96×standard deviation).
Fig. 3Bland-Altman plot for the (A) women not progressing to type 2 diabetes mellitus (NONPROG) and (B) women progressing to type 2 diabetes mellitus (PROG) subgroups at baseline and follow-up. The continuous line represents the mean of the difference between minimal model glucose effectiveness (SG) and calculated SG (CSG); the dash-dotted lines represent the limits of agreement (mean±1.96×standard deviation).
Fig. 4Glucose effectiveness assessed by (A) minimal model glucose effectiveness (SG) and (B) calculated SG (CSG) at baseline and follow-up in the women not progressing to type 2 diabetes mellitus at follow-up (NONPROG) and women progressing to type 2 diabetes mellitus (PROG) subgroups. Data are expressed as mean±standard error of the mean. aStatistically significant difference (P<0.05).
Table 1Characteristics of the participants
Characteristic |
Sex, male/female |
Age, yr |
BMI, kg/m2
|
Basal glucose, mmol/L |
Basal insulin, pmol/L |
ND |
18/90 |
33.1±1.0 |
28.2±0.7 |
5.0±0.1 |
67.5±4.5 |
T2DM |
49/24 |
48.8±1.9 |
30.0±0.6 |
9.1±0.3 |
86.4±7.3 |
pGDM |
|
|
|
|
|
NONPROG |
|
|
|
|
|
Baseline |
0/43 |
33.9±0.6 |
25.3±0.6 |
4.7±0.1 |
50.5±5.0 |
Follow-up |
|
38.9±0.6 |
25.2±0.6 |
4.9±0.1 |
58.5±4.8 |
PROG |
|
|
|
|
|
Baseline |
0/14 |
36.6±1.3 |
32.5±1.8 |
5.7±0.5 |
92.1±24.6 |
Follow-up |
|
41.3±1.5 |
34.2±2.1 |
6.9±0.4 |
107.7±17.1 |